Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LIGAND PHARMACEUTICALS INCLGND · Entity 3825 | CLO & Secretary | October 02, 2026 | October 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LIGAND PHARMACEUTICALS INC
Report date October 02, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,854 |
Ending reported balance
After 2026-10-02 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2026-10-02 · Exercise / conversion · Acquired 340 · Balance 36,854 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1. Row 2 · 2026-10-02 · Sale · Disposed 833 · Balance 36,021 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1. F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $302.14 to $303.06. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2026-10-02 · Sale · Disposed 1,976 · Balance 34,045 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1. F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $303.14 to $304.12. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2026-10-02 · Sale · Disposed 1,535 · Balance 32,510 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1. F4: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $304.19 to $305.01. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 5 · 2026-10-02 · Sale · Disposed 404 · Balance 32,106 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1. F5: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $305.71 to $306.46. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 6 · 2026-10-02 · Sale · Disposed 235 · Balance 31,871 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1. F6: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $306.72 to $307.54. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 7 · 2026-10-02 · Sale · Disposed 17 · Balance 31,854 F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.27 · Expires 2032-08-01 | Direct | 29,104 |
Reported balance
After 2026-10-02 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-02 · Exercise / conversion · Disposed 340 · Balance 29,104 F7: The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1.
F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $302.14 to $303.06. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $303.14 to $304.12. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $304.19 to $305.01. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $305.71 to $306.46. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $306.72 to $307.54. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7: The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 02, 2026 Filed Oct 6, 2026 20:35 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 340 | $0.00 Strike: $52.27 | $0.00 |
DisclosureSEC source: 0001950232-26-000003 · wk-form4_1791318933.xml · derivative · entry 8 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,104 Underlying: Common Stock · 340 shares Expires 2032-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter. Read SEC document |
| October 02, 2026 Filed Oct 6, 2026 20:35 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 17 | $307.74 | $5,231.58 |
DisclosureSEC source: 0001950232-26-000003 · wk-form4_1791318933.xml · nonDerivative · entry 7 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,854 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1. Read SEC document |
| October 02, 2026 Filed Oct 6, 2026 20:35 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 235 | $307.19 | $72,189.91 |
DisclosureSEC source: 0001950232-26-000003 · wk-form4_1791318933.xml · nonDerivative · entry 6 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,871 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1. F6 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $306.72 to $307.54. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 02, 2026 Filed Oct 6, 2026 20:35 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 404 | $306.18 | $123,698.09 |
DisclosureSEC source: 0001950232-26-000003 · wk-form4_1791318933.xml · nonDerivative · entry 5 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,106 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $305.71 to $306.46. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 02, 2026 Filed Oct 6, 2026 20:35 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 1,535 | $304.52 | $467,431.14 |
DisclosureSEC source: 0001950232-26-000003 · wk-form4_1791318933.xml · nonDerivative · entry 4 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,510 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $304.19 to $305.01. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 02, 2026 Filed Oct 6, 2026 20:35 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 1,976 | $303.54 | $599,803.73 |
DisclosureSEC source: 0001950232-26-000003 · wk-form4_1791318933.xml · nonDerivative · entry 3 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,045 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $303.14 to $304.12. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 02, 2026 Filed Oct 6, 2026 20:35 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 833 | $302.51 | $251,991.41 |
DisclosureSEC source: 0001950232-26-000003 · wk-form4_1791318933.xml · nonDerivative · entry 2 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,021 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $302.14 to $303.06. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 02, 2026 Filed Oct 6, 2026 20:35 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 340 | $52.27 | $17,771.80 |
DisclosureSEC source: 0001950232-26-000003 · wk-form4_1791318933.xml · nonDerivative · entry 1 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,854 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 4, 2026, in accordance with Rule 10b5-1. Read SEC document |
| September 03, 2026 Filed Sep 8, 2026 22:34 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 400 | $288.98 | $115,591.68 |
DisclosureSEC source: 0002001011-26-000137 · edgardoc.xml · nonDerivative · entry 5 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,514 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 04, 2026, in accordance with Rule 10b5-1. F6 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $288.5500 to $289.4300. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 03, 2026 Filed Sep 8, 2026 22:34 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 385 | $287.53 | $110,697.24 |
DisclosureSEC source: 0002001011-26-000137 · edgardoc.xml · nonDerivative · entry 4 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,914 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 04, 2026, in accordance with Rule 10b5-1. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $287.0500 to $287.6600. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 03, 2026 Filed Sep 8, 2026 22:34 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 2,115 | $286.36 | $605,649.07 |
DisclosureSEC source: 0002001011-26-000137 · edgardoc.xml · nonDerivative · entry 3 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,299 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 04, 2026, in accordance with Rule 10b5-1. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $285.8000 to $286.7700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 03, 2026 Filed Sep 8, 2026 22:34 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 1,800 | $285.17 | $513,300.78 |
DisclosureSEC source: 0002001011-26-000137 · edgardoc.xml · nonDerivative · entry 2 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,414 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 04, 2026, in accordance with Rule 10b5-1. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $284.7500 to $285.7000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 03, 2026 Filed Sep 8, 2026 22:34 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 300 | $283.99 | $85,195.62 |
DisclosureSEC source: 0002001011-26-000137 · edgardoc.xml · nonDerivative · entry 1 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,214 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 04, 2026, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $283.4300 to $284.1550. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 22:42 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $52.27 | $0.00 |
DisclosureSEC source: 0002001011-26-000111 · edgardoc.xml · derivative · entry 12 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,444 Underlying: Common Stock · 5,000 shares Expires 2032-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F12 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 22:42 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 409 | $292.82 | $119,763.01 |
DisclosureSEC source: 0002001011-26-000111 · edgardoc.xml · nonDerivative · entry 11 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,514 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F11 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $292.78 to $292.89. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 22:42 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 991 | $291.71 | $289,086.49 |
DisclosureSEC source: 0002001011-26-000111 · edgardoc.xml · nonDerivative · entry 10 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,923 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F10 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $291.57 to $292.47. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 22:42 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 200 | $290.60 | $58,120.00 |
DisclosureSEC source: 0002001011-26-000111 · edgardoc.xml · nonDerivative · entry 9 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,914 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F9 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $290.48 to $290.72. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 22:42 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 503 | $289.80 | $145,770.51 |
DisclosureSEC source: 0002001011-26-000111 · edgardoc.xml · nonDerivative · entry 8 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,114 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F8 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $289.33 to $290.18. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 22:42 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 356 | $288.75 | $102,794.86 |
DisclosureSEC source: 0002001011-26-000111 · edgardoc.xml · nonDerivative · entry 7 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,617 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F7 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $288.32 to $289.20. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 22:42 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 1,214 | $287.77 | $349,356.54 |
DisclosureSEC source: 0002001011-26-000111 · edgardoc.xml · nonDerivative · entry 6 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,973 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F6 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $287.30 to $288.27. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 22:42 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 1,032 | $286.80 | $295,974.30 |
DisclosureSEC source: 0002001011-26-000111 · edgardoc.xml · nonDerivative · entry 5 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,187 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $286.28 to $287.17. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 22:42 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 157 | $285.74 | $44,860.50 |
DisclosureSEC source: 0002001011-26-000111 · edgardoc.xml · nonDerivative · entry 4 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,219 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $285.28 to $285.90. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 22:42 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 33 | $284.55 | $9,390.25 |
DisclosureSEC source: 0002001011-26-000111 · edgardoc.xml · nonDerivative · entry 3 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,376 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $284.28 to $284.58. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 22:42 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 105 | $284.14 | $29,834.44 |
DisclosureSEC source: 0002001011-26-000111 · edgardoc.xml · nonDerivative · entry 2 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,409 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $283.24 to $284.23. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 22:42 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 5,000 | $52.27 | $261,350.00 |
DisclosureSEC source: 0002001011-26-000111 · edgardoc.xml · nonDerivative · entry 1 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 21:11 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $52.27 | $0.00 |
DisclosureSEC source: 0002001011-26-000108 · edgardoc.xml · derivative · entry 11 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,444 Underlying: Common Stock · 5,000 shares Expires 2032-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F11 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 21:11 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 600 | $317.15 | $190,291.02 |
DisclosureSEC source: 0002001011-26-000108 · edgardoc.xml · nonDerivative · entry 10 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,514 F2 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F10 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $316.7000 to $317.4300. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 21:11 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 900 | $315.78 | $284,199.75 |
DisclosureSEC source: 0002001011-26-000108 · edgardoc.xml · nonDerivative · entry 9 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,114 F2 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F9 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $315.4400 to $316.2600. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 21:11 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 100 | $314.58 | $31,457.88 |
DisclosureSEC source: 0002001011-26-000108 · edgardoc.xml · nonDerivative · entry 8 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,014 F2 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F8 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $314.3100 to $314.5900. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 21:11 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 700 | $313.46 | $219,420.18 |
DisclosureSEC source: 0002001011-26-000108 · edgardoc.xml · nonDerivative · entry 7 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,114 F2 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F7 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $313.1300 to $314.0100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 21:11 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 1,081 | $312.28 | $337,572.95 |
DisclosureSEC source: 0002001011-26-000108 · edgardoc.xml · nonDerivative · entry 6 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,814 F2 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F6 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $312.1050 to $312.5300. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 21:11 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 1,119 | $311.72 | $348,814.68 |
DisclosureSEC source: 0002001011-26-000108 · edgardoc.xml · nonDerivative · entry 5 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,895 F2 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $311.0900 to $312.0400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 21:11 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 104 | $310.20 | $32,261.04 |
DisclosureSEC source: 0002001011-26-000108 · edgardoc.xml · nonDerivative · entry 4 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,014 F2 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $310.0100 to $310.2100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 21:11 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 396 | $308.99 | $122,359.49 |
DisclosureSEC source: 0002001011-26-000108 · edgardoc.xml · nonDerivative · entry 3 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,118 F2 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $308.6300 to $309.6000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 21:11 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 5,000 | $52.27 | $261,350.00 |
DisclosureSEC source: 0002001011-26-000108 · edgardoc.xml · nonDerivative · entry 2 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. Read SEC document |
| June 30, 2026 Filed Jul 6, 2026 21:11 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | OtherCommon Stock | 132 | $160.71 | $21,213.65 |
DisclosureSEC source: 0002001011-26-000108 · edgardoc.xml · nonDerivative · entry 1 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,514 F1 · kind: These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 22:22 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $52.27 | $0.00 |
DisclosureSEC source: 0002001011-26-000083 · edgardoc.xml · derivative · entry 9 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,444 Underlying: Common Stock · 5,000 shares Expires 2032-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F8 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 22:22 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 200 | $230.41 | $46,082.00 |
DisclosureSEC source: 0002001011-26-000083 · edgardoc.xml · nonDerivative · entry 8 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,382 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 22:22 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 1,216 | $229.47 | $279,032.60 |
DisclosureSEC source: 0002001011-26-000083 · edgardoc.xml · nonDerivative · entry 7 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,582 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F7 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $229.0900 to $230.0000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 22:22 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 584 | $228.57 | $133,487.10 |
DisclosureSEC source: 0002001011-26-000083 · edgardoc.xml · nonDerivative · entry 6 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,798 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F6 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $228.0500 to $228.9650. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 22:22 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 400 | $226.78 | $90,711.76 |
DisclosureSEC source: 0002001011-26-000083 · edgardoc.xml · nonDerivative · entry 5 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,382 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $226.5250 to $227.0100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 22:22 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 1,432 | $225.97 | $323,585.03 |
DisclosureSEC source: 0002001011-26-000083 · edgardoc.xml · nonDerivative · entry 4 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,782 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $225.5200 to $226.3700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 22:22 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 677 | $225.20 | $152,459.25 |
DisclosureSEC source: 0002001011-26-000083 · edgardoc.xml · nonDerivative · entry 3 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,214 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $224.5100 to $225.4600. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 22:22 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 491 | $223.95 | $109,957.83 |
DisclosureSEC source: 0002001011-26-000083 · edgardoc.xml · nonDerivative · entry 2 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,891 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $223.4250 to $224.3800. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 22:22 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 5,000 | $52.27 | $261,350.00 |
DisclosureSEC source: 0002001011-26-000083 · edgardoc.xml · nonDerivative · entry 1 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,382 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. Read SEC document |
| May 01, 2026 Filed May 5, 2026 00:20 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $52.27 | $0.00 |
DisclosureSEC source: 0002001011-26-000046 · edgardoc.xml · derivative · entry 9 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,444 Underlying: Common Stock · 5,000 shares Expires 2032-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F9 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter. Read SEC document |
| May 01, 2026 Filed May 5, 2026 00:20 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 800 | $234.02 | $187,214.16 |
DisclosureSEC source: 0002001011-26-000046 · edgardoc.xml · nonDerivative · entry 8 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,382 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F8 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $233.8200 to $234.1100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2026 Filed May 5, 2026 00:20 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 1,420 | $232.92 | $330,749.24 |
DisclosureSEC source: 0002001011-26-000046 · edgardoc.xml · nonDerivative · entry 7 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,182 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F7 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $232.5400 to $233.3300. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2026 Filed May 5, 2026 00:20 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 780 | $232.04 | $180,991.12 |
DisclosureSEC source: 0002001011-26-000046 · edgardoc.xml · nonDerivative · entry 6 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,602 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F6 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $231.5200 to $232.4900. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2026 Filed May 5, 2026 00:20 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 370 | $230.87 | $85,421.60 |
DisclosureSEC source: 0002001011-26-000046 · edgardoc.xml · nonDerivative · entry 5 Reardon Andrew · CIK 0001950232 · CLO & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,382 F1 · shares: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $230.4300 to $231.3500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.